Are We Missing Something About the Maximum Dosing of Botulinum Toxin Type A1 in Adult and Pediatric Patients with Spasticity?

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2024 Dec 27

PMID 39728771

Authors

Alessandro Picelli

Rita Di Censo

Stefano Tamburin

Nicola Smania

Mirko Filippetti

Affiliations

Soon will be listed here.

Abstract

Botulinum toxin type A1 is a first-line treatment for adult and pediatric spasticity. However, when considering the quantity of 150 kDa neurotoxin protein in relation to patient weight and the maximum recommended dose for treating adult and pediatric patients with spasticity, several concerns arise. First, the therapeutic margin (the ratio of the actual maximum quantity of toxin recommended for treating adult spasticity to its median lethal dose) appears to be relevant. Second, there is no consistency between adult and pediatric dosing of botulinum toxin type A1 for spasticity. The third point concerns the suitability of the recommended doses for treating spasticity in pediatric patients. Based on the average body weight of American children and adolescents, the maximum weight-based doses for abobotulinumtoxinA and onabotulinumtoxinA could be administered to children as young as 9 years old. Additionally, the maximum weight-based dose for incobotulinumtoxinA could be administered to children as young as 6 years old. The final point concerns managing the maximum dose of BoNT/A1 in pediatric patients with spasticity who weigh more than 25 kg for incobotulinumtoxinA, or more than 34 kg for abobotulinumtoxinA and onabotulinumtoxinA. No labeled recommendations are given on the weight cut-off for transitioning to adult dosing in pediatric patients.

References

Wissel J, Ward A, Erztgaard P, Bensmail D, Hecht M, Lejeune T . European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009; 41(1):13-25. DOI: 10.2340/16501977-0303. View

Dong J, Helveston E, William Hanke C . The 200-Year Timeline on Botulinum Toxin: From Biologic Poison to Wonder Drug. J Drugs Dermatol. 2024; 23(1):1357-1359. DOI: 10.36849/JDD.7288. View

Bensmail D, Hanschmann A, Wissel J . Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J Med Econ. 2014; 17(9):618-25. DOI: 10.3111/13696998.2014.925462. View

Pirazzini M, Rossetto O, Eleopra R, Montecucco C . Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017; 69(2):200-235. PMC: 5394922. DOI: 10.1124/pr.116.012658. View

Simpson D, Hallett M, Ashman E, Comella C, Green M, Gronseth G . Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016; 86(19):1818-26. PMC: 4862245. DOI: 10.1212/WNL.0000000000002560. View

Pirazzini M, Montecucco C, Rossetto O . Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update. Arch Toxicol. 2022; 96(6):1521-1539. PMC: 9095541. DOI: 10.1007/s00204-022-03271-9. View

Rossetto O, Montecucco C . Tables of Toxicity of Botulinum and Tetanus Neurotoxins. Toxins (Basel). 2019; 11(12). PMC: 6950492. DOI: 10.3390/toxins11120686. View

Vova J, Green M, Brandenburg J, Davidson L, Paulson A, Deshpande S . A consensus statement on the use of botulinum toxin in pediatric patients. PM R. 2021; 14(9):1116-1142. DOI: 10.1002/pmrj.12713. View

Li S, Francisco G, Rymer W . A New Definition of Poststroke Spasticity and the Interference of Spasticity With Motor Recovery From Acute to Chronic Stages. Neurorehabil Neural Repair. 2021; 35(7):601-610. DOI: 10.1177/15459683211011214. View

10.

Brodsky M, Swope D, Grimes D . Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y). 2013; 2. PMC: 3570036. DOI: 10.7916/D88W3C1M. View

11.

Brin M, Nelson M, Ashourian N, Brideau-Andersen A, Maltman J . Update on Non-Interchangeability of Botulinum Neurotoxin Products. Toxins (Basel). 2024; 16(6). PMC: 11209304. DOI: 10.3390/toxins16060266. View

12.

Wheeler A, Smith H . Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013; 306:124-46. DOI: 10.1016/j.tox.2013.02.006. View

13.

Li S, Francisco G . The Use of Botulinum Toxin for Treatment of Spasticity. Handb Exp Pharmacol. 2019; 263:127-146. DOI: 10.1007/164_2019_315. View

14.

Jabbari B . History of Botulinum Toxin Treatment in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2016; 6:394. PMC: 5133258. DOI: 10.7916/D81836S1. View

15.

Intiso D, Simone V, Bartolo M, Santamato A, Ranieri M, Gatta M . High Dosage of Botulinum Toxin Type A in Adult Subjects with Spasticity Following Acquired Central Nervous System Damage: Where Are We at?. Toxins (Basel). 2020; 12(5). PMC: 7291232. DOI: 10.3390/toxins12050315. View

16.

Fryar C, Carroll M, Gu Q, Afful J, Ogden C . Anthropometric Reference Data for Children and Adults: United States, 2015-2018. Vital Health Stat 3. 2021; (36):1-44. View

17.

Suputtitada A, Chatromyen S, Chen C, Simpson D . Best Practice Guidelines for the Management of Patients with Post-Stroke Spasticity: A Modified Scoping Review. Toxins (Basel). 2024; 16(2). PMC: 10892074. DOI: 10.3390/toxins16020098. View

18.

Dressler D, Kopp B, Adib Saberi F . Botulinum toxin dosing in arm muscles: contextual factors. J Neural Transm (Vienna). 2021; 128(3):315-319. PMC: 7969489. DOI: 10.1007/s00702-021-02307-1. View

19.

Santamato A . High Doses of Botulinum Toxin Type A for the Treatment of Post-Stroke Spasticity: Rationale for a Real Benefit for the Patients. Toxins (Basel). 2022; 14(5). PMC: 9145804. DOI: 10.3390/toxins14050332. View

20.

Fryar C, Kruszon-Moran D, Gu Q, Carroll M, Ogden C . Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Children and Adolescents: United States, 1999-2018. Natl Health Stat Report. 2021; (160):1-24. View